| Drug Name | GPCR-targeted Project 002 |
| Description |
Sphingosine 1-phosphate (S1P) is a member of a class of lipids called sphingolipids that are involved in stimulating angiogenesis and mediating fibrosis. A first-in-class monoclonal antibody targeting sphingosine 1-phosphate receptor 1 (S1PR1) is developed for the treatment of autoimmune diseases such as multiple sclerosis and inflammation. |
| Target | Sphingosine 1-phosphate receptor 1 (S1PR1) |
| Drug Modality | Monoclonal antibody |
| Indication | Autoimmune diseases; Inflammation |
| Product Category | Biologic |
| Mechanism of Action | S1PR1 agonists |
| Status | Discovery |
| Patent | Granted |
We look forward to hearing from you.
Protheragen's business is growing rapidly after founded in Ronkonkoma, New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.
 |
Protheragen Inc. |
 |
Quick Links |